Purine

Purine

SCHEMBL5578775

[PbH2].c1ncc2nc[nH]c2n1

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.37
KDM4B O94953 1/20 0.37
KDM5C P41229 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
KDM3A Q9Y4C1 1/20 0.37
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
HPGD P15428 2/20 0.35
TP53 P04637 1/20 0.35
PTGS1 P23219 1/20 0.35
HBB P68871 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 2/20 0.34
APEX1 P27695 1/20 0.34
RECQL P46063 1/20 0.34
BLM P54132 1/20 0.34
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Purine SCHEMBL3157 0.98
Purine SCHEMBL2120547 0.98 KDM4A (0.38) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL29456595 0.98
Purine SCHEMBL6421376 0.98 KDM4A (0.38) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL311318 0.95 KDM4A (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL6438162 0.95 KDM4A (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL5611476 0.95 KDM4A (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL37119 0.95 KDM4A (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL7787135 0.95 KDM4A (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
Purine SCHEMBL1150716 0.95 KDM4A (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118355914-A Use of purine compounds for controlling pathogenic microorganisms 兰州大学 2024-07-19 CN disclosed
US-20070207512-A1 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS PLIVA D.D. (HR) 2007-09-06 US disclosed
CN-1268765-C Structure-based drug design methods for idenfitying D-ALA-D-ALA ligase inhibitors as antibacterial drugs ESSENTIAL THERAPEUTICS INC (US) 2006-08-09 CN disclosed
CN-1539020-A Structure-based drug design methods for idenfitying D-ALA-D-ALA ligase inhibitors as antibacterial drugs ��������ҽѧ���޹�˾ 2004-10-20 CN disclosed
EP-1412516-A4 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS ESSENTIAL THERAPEUTICS INC (US) 2004-09-08 EP disclosed
EP-1412516-A2 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS Essential Therapeutics, Inc. (US) 2004-04-28 EP disclosed
US-20030119061-A1 Structure-based drug design methods for identifying D-Ala-D-Ala ligase inhibitors as antibacterial drugs ESSENTIAL THERAPEUTICS, INC. 2003-06-26 US disclosed
WO-2003002063-A2 STRUCTURE-BASED DRUG DESIGN METHODS FOR IDENTIFYING D-ALA-D-ALA LIGASE INHIBITORS AS ANTIBACTERIAL DRUGS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO disclosed